ReviewMedical oncology (Northwood, London, England)2026
Histologic and molecular transformation from non-small cell to small cell lung cancer: insights in the era of expanding treatment options.
Review in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains one of the leading causes of cancer-related mortality worldwide, with increasing attention being paid to the histologic transformation between non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). This review provides a comprehensive overview of the current understanding of NSCLC-to-SCLC transformation, covering the classification of NSCLC subtypes, advances in targeted therapy for epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma, clinical manifestations of SCLC transformation, diagnostic technologies, therapeutic strategies, ongoing controversies, and future perspectives. By integrating extensive evidence from the literature, we systematically analyze the clinical findings, molecular mechanisms, diagnostic approaches, and treatment modalities related to this phenomenon. Our aim is to offer clinicians and researchers a thorough and insightful reference to facilitate further investigation into NSCLC-to-SCLC transformation and ultimately improve therapeutic outcomes and prognosis for patients with lung cancer.
Indexed as
Identifiers
42900325What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.